BTK
BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 167 products of "BTK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Formula:C36H40FN9O3Purity:98.28% - 99.76%Color and Shape:SolidMolecular weight:665.76Ref: TM-T12542
1mg94.00€5mg222.00€1mL*10mM (DMSO)325.00€10mg356.00€25mg620.00€50mg893.00€100mg1,251.00€500mg2,502.00€MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Formula:C41H41N9O8Purity:95.93% - 97%Color and Shape:SolidMolecular weight:787.82Ref: TM-T16157
1mg92.00€5mg177.00€1mL*10mM (DMSO)231.00€10mg269.00€25mg510.00€50mg692.00€100mg888.00€200mg1,251.00€ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Formula:C25H23ClN4O4Purity:98.68% - 99.63%Color and Shape:SolidMolecular weight:478.93Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Formula:C24H25N5O3Purity:99.94%Color and Shape:SolidMolecular weight:431.49Ref: TM-T10629
1mg34.00€2mg49.00€5mg74.00€1mL*10mM (DMSO)82.00€10mg98.00€25mg215.00€50mg356.00€100mg434.00€AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Formula:C33H31FN6O3Purity:≥95%Color and Shape:SolidMolecular weight:578.64IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formula:C22H22N6OPurity:99.8% - 99.88%Color and Shape:SolidMolecular weight:386.45Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Formula:C26H25N3O3Purity:97.77% - 99.54%Color and Shape:SolidMolecular weight:427.49Ref: TM-T12317
1mg86.00€5mg177.00€1mL*10mM (DMSO)205.00€10mg299.00€25mg492.00€50mg682.00€100mg897.00€500mg1,791.00€Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Formula:C25H23ClN6O3Purity:99.27% - 99.95%Color and Shape:SolidMolecular weight:490.94BTK-IN-40
CAS:BTK-IN-40 (compound 375) is an inhibitor of BTK.Formula:C20H25N7O2Color and Shape:SolidMolecular weight:395.46PROTAC BTK Degrader-5
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity byFormula:C52H57ClFN9O6Purity:98%Color and Shape:SolidMolecular weight:958.52Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Formula:C8H6BrN3SPurity:99.94%Color and Shape:SolidMolecular weight:256.12DBt-10
DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].Formula:C68H86ClFN16O6Purity:98%Color and Shape:SolidMolecular weight:1277.96PROTAC BTK Degrader-6
CAS:PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expressionFormula:C45H47N11O6Purity:98%Color and Shape:SolidMolecular weight:837.92FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Color and Shape:LiquidBTK-IN-5
CAS:BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Formula:C23H32N4O5Color and Shape:SolidMolecular weight:444.532FDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Color and Shape:Odour SolidBTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Color and Shape:Odour SolidGBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formula:C44H47N9O6Purity:98%Color and Shape:SolidMolecular weight:797.9Acalabrutinib enantiomer
CAS:R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.
Formula:C26H23N7O2Purity:97.27%Color and Shape:SolidMolecular weight:465.51CNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Formula:C48H68N10O9SPurity:98%Color and Shape:SolidMolecular weight:961.18evobrutinib
CAS:Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in theFormula:C25H27N5O2Purity:98.03% - 99.58%Color and Shape:SolidMolecular weight:429.51Ref: TM-T4387
1mg42.00€1mL*10mM (DMSO)87.00€5mg88.00€10mg127.00€25mg227.00€50mg329.00€100mg472.00€500mg1,017.00€BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formula:C23H23ClFN7O2Color and Shape:SolidMolecular weight:483.93BTK inhibitor 17
CAS:BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.Formula:C25H24N6O3Purity:99.57% - 99.88%Color and Shape:SolidMolecular weight:456.5Ref: TM-T9706
1mg89.00€5mg166.00€1mL*10mM (DMSO)166.00€10mg250.00€25mg403.00€50mg532.00€100mg745.00€200mg982.00€Atuzabrutinib
CAS:Atuzabrutinib (SAR 444727) is a selective BTK inhibitor and can be used to study arthritis in rheumatoid rodents and pemphigus vulgaris.Formula:C30H30FN7O2Purity:97.27% - 99.38%Color and Shape:SolidMolecular weight:539.6Ref: TM-T39056
1mg69.00€5mg147.00€1mL*10mM (DMSO)170.00€10mg224.00€25mg358.00€50mg512.00€100mg707.00€200mg973.00€PCI-33380
CAS:PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.Formula:C46H52BF2N11O3Purity:98%Color and Shape:SolidMolecular weight:855.8Ibrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Formula:C56H80N12O9SPurity:98%Color and Shape:SolidMolecular weight:1097.39TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Color and Shape:Odour SolidDD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formula:C55H62N10O8Color and Shape:SolidMolecular weight:991.163BTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formula:C25H24F3N7O3Color and Shape:SolidMolecular weight:527.508DCAF1 binder 2
DCAF1 Binder 2, an E3 ligase ligand, is implicated in BRD9, kinase, and selective Bruton's tyrosine kinase (BTK) degradation.Color and Shape:Odour SolidL18I
L18I is a PROTAC (Proteolysis Targeting Chimera) that targets Btk to mitigate inflammation in autoimmune diseases. The components of L18I include the PROTAC target protein ligand IBT6A, the PROTAC linker Propargyl-PEG3-alcohol, and the E3 ubiquitin ligase ligand Lenalidomide-Br. Notably, the active control for the target protein ligand is IBT6A-CO-ethyne, while the conjugate of the E3 ubiquitin ligase ligand with the linker is Lenalidomide-C3-PEG3-N3.Formula:C47H51N11O8Color and Shape:SolidMolecular weight:897.98I-As-1
I-As-1 is a potent inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 2.35 nM. It exhibits antiproliferative activity against Ramos cells and OCI-LY10 cells, with IC50 values of 0.52 μM and 0.11 μM, respectively.Formula:C26H27AsN6O2S2Molecular weight:594.08529PROTAC BTK Degrader-12
CAS:PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.Formula:C47H54N12O4Color and Shape:SolidMolecular weight:851.01PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Formula:C43H43N9O4Color and Shape:SolidMolecular weight:749.86PROTAC BTK Degrader-10
CAS:PROTAC BTK Degrader-10 (Example 1P) is a PROTAC compound that targets BTK for degradation. It is applicable in the research of chronic lymphocytic leukemia (CLL). [Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase Cereblon].Formula:C42H49N11O4Color and Shape:SolidMolecular weight:771.91Ibrutinib dimer
CAS:Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Formula:C50H48N12O4Purity:98%Color and Shape:SolidMolecular weight:880.99PROTAC BTK Degrader-11
CAS:PROTAC BTK Degrader-11 is a PROTAC degrader that targets and degrades BTK with a DC50 of 1.7 nM. It is utilized in oncological research.Formula:C48H55N11O4Color and Shape:SolidMolecular weight:850.02SJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formula:C41H45ClN8O7Purity:98%Color and Shape:SolidMolecular weight:797.3PROTAC BTK Degrader-13
PROTAC BTK Degrader-13 (Compound 25) is a targeted BTK PROTAC degrader with a DC50 of 0.27 μM. It inhibits BTK activity with an IC50 of 0.44 μM and suppresses IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. This compound also inhibits the p38 MAPK signaling pathway, thereby blocking the activation of the BCR (B cell receptor) signaling pathway. [Pink: ligand for target protein BTK ligand 15; Black: linker; Blue: ligand for E3 ligase cereblon]Formula:C33H30N6O7Color and Shape:SolidMolecular weight:622.63NRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Formula:C43H51N11O6Color and Shape:SolidMolecular weight:817.94QL-X-138 HCl
QL-X-138 HCl is a BTK/MNK dual kinase inhibitor with anticancer activity and anti-dengue virus 2 activity that inhibits BTK, MNK1, and MNK2 kinases.Formula:C25H20ClN5O2Purity:99.25%Color and Shape:SoildMolecular weight:457.91PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Formula:C47H54F2N8O13Color and Shape:SolidMolecular weight:976.97PROTAC BTK Degrader-8
PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.Formula:C80H94F2N14O20P2Molecular weight:1670.62121PROTAC BTK Degrader-9
PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.Formula:C46H52FN13O5Molecular weight:885.41984BCPyr
CAS:BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formula:C58H65F2N11O8Color and Shape:SolidMolecular weight:1082.224BIIB091
CAS:BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.Formula:C28H34N10O2Color and Shape:SolidMolecular weight:542.648N-piperidine Ibrutinib hydrochloride
CAS:N-piperidine Ibrutinib hydrochloride is a BTK inhibitor that inhibits WT BTK and C481S BTK , which inhibits the growth and proliferation of cancer cells.Formula:C22H23ClN6OPurity:98.83%Color and Shape:SolidMolecular weight:422.91NX-5948
CAS:NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.Formula:C42H54N12O5Purity:98.29%Color and Shape:SolidMolecular weight:806.96Zanubrutinib-d5
Zanubrutinib-d5 (BGB-3111-d5) is a deuterium-labeled Zanubrutinib, an orally available Bruton's tyrosine kinase inhibitor for the study of B-cell malignancies.Formula:C27H29N5O3Purity:>99.99%Color and Shape:SolidMolecular weight:476.58Poseltinib
CAS:Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.Formula:C26H26N6O3Purity:99.98%Color and Shape:SolidMolecular weight:470.52Ref: TM-T4413
2mg34.00€5mg49.00€1mL*10mM (DMSO)50.00€10mg75.00€25mg146.00€50mg260.00€100mg409.00€200mg590.00€Elsubrutinib
CAS:Elsubrutinib (ABBV-105) is an orally active, selective, and irreversible BTK inhibitor with an IC50 of 0.18 μM for the catalytic domain of BTK.Formula:C17H19N3O2Purity:99.77%Color and Shape:SolidMolecular weight:297.36Ref: TM-T39130
1mg145.00€5mg250.00€10mg340.00€1mL*10mM (DMSO)356.00€25mg573.00€50mg879.00€100mg1,314.00€GDC-0834
CAS:GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse andFormula:C33H36N6O3SColor and Shape:SolidMolecular weight:596.74IBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Formula:C22H23ClN6OColor and Shape:SolidMolecular weight:422.91Anti-BTK Antibody (3G585)
Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.Color and Shape:Odour Liquid(Z)-LFM-A13
CAS:(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.Formula:C11H8Br2N2O2Purity:99.88%Color and Shape:SolidMolecular weight:360Fenebrutinib
CAS:Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
Formula:C37H44N8O4Purity:98.26% - 98.94%Color and Shape:SolidMolecular weight:664.8PCI 29732
CAS:PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.Formula:C22H21N5OPurity:99.81%Color and Shape:SolidMolecular weight:371.43CGI-1746
CAS:CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.Formula:C34H37N5O4Purity:97.69% - 97.88%Color and Shape:SolidMolecular weight:579.69BIIB068
CAS:BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.Formula:C23H29N7O2Purity:97.98%Color and Shape:SolidMolecular weight:435.52Ref: TM-T9192
1mg46.00€5mg90.00€1mL*10mM (DMSO)100.00€10mg152.00€25mg264.00€50mg398.00€100mg532.00€200mg705.00€BMS-986142
CAS:BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).Formula:C32H30F2N4O4Purity:99.44% - 99.76%Color and Shape:SolidMolecular weight:572.6Ref: TM-T5138
1mg105.00€2mg165.00€5mg289.00€1mL*10mM (DMSO)358.00€10mg447.00€25mg715.00€50mg964.00€100mg1,243.00€200mg1,693.00€CHMFL-BMX-078
CAS:CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.Formula:C33H35N7O6Purity:>99.99%Color and Shape:SolidMolecular weight:625.67N-piperidine Ibrutinib
CAS:N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively.Formula:C22H22N6OPurity:96.65%Color and Shape:SolidMolecular weight:386.45Tuxobertinib
CAS:Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.Formula:C29H29ClN6O4Purity:99.22%Color and Shape:SolidMolecular weight:561.03Ref: TM-T9072
2mg38.00€5mg57.00€1mL*10mM (DMSO)71.00€10mg90.00€25mg178.00€50mg334.00€100mg497.00€200mg712.00€(Rac)-IBT6A
CAS:(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formula:C22H22N6OPurity:99.24%Color and Shape:SolidMolecular weight:386.45Ref: TM-T10626
1mg44.00€2mg57.00€1mL*10mM (DMSO)92.00€5mg93.00€10mg120.00€25mg215.00€50mg313.00€100mg439.00€200mg628.00€zanubrutinib
CAS:Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).Formula:C27H29N5O3Purity:98.42% - 99.76%Color and Shape:SolidMolecular weight:471.55Ref: TM-T7584
1mg59.00€5mg137.00€1mL*10mM (DMSO)142.00€10mg236.00€25mg492.00€50mg737.00€100mg1,018.00€Ibrutinib deacryloylpiperidine
CAS:Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.Formula:C17H13N5OPurity:99.47%Color and Shape:SolidMolecular weight:303.32TL-895
CAS:TL-895 is a potent, selective ATP-competitive BTK inhibitor (IC50 = 1.5 nM, Ki = 11.9 nM).Formula:C25H26FN5O2Purity:99.96%Color and Shape:SolidMolecular weight:447.5Ref: TM-T9705
2mg39.00€5mg60.00€1mL*10mM (DMSO)60.00€10mg87.00€25mg172.00€50mg266.00€100mg391.00€200mg555.00€Larotinib mesylate hydrate
CAS:Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nMFormula:C26H36ClFN4O11S2Color and Shape:SolidMolecular weight:699.17ONO-4059 analog
CAS:ONO-4059 analog (ONO-WG-307)ue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.Formula:C25H24N6O3Purity:99.25%Color and Shape:SolidMolecular weight:456.5Ref: TM-T6921
1mg43.00€2mg56.00€1mL*10mM (DMSO)90.00€5mg93.00€10mg137.00€25mg264.00€50mg439.00€100mg627.00€Olmutinib
CAS:Olmutinib is an oral mutant-specific EGFR inhibitor for cancer treatment with potential lower toxicity.Formula:C26H26N6O2SPurity:99.14% - 99.63%Color and Shape:SolidMolecular weight:486.59Ref: TM-T6918
2mg37.00€5mg54.00€1mL*10mM (DMSO)56.00€10mg84.00€25mg130.00€50mg170.00€100mg268.00€200mg437.00€CNX-774
CAS:CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).Formula:C26H22FN7O3Purity:97.35% - 99.11%Color and Shape:SolidMolecular weight:499.5Ref: TM-T2302
1mg38.00€2mg50.00€5mg84.00€1mL*10mM (DMSO)88.00€10mg119.00€25mg222.00€50mg369.00€100mg537.00€500mg1,161.00€RN486
CAS:RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).Formula:C35H35FN6O3Purity:99.38%Color and Shape:SolidMolecular weight:606.69Remibrutinib
CAS:Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood.Formula:C27H27F2N5O3Purity:99.5% - 99.81%Color and Shape:SolidMolecular weight:507.53Ref: TM-T16730
1mg92.00€5mg210.00€1mL*10mM (DMSO)235.00€10mg340.00€25mg572.00€50mg713.00€100mg1,099.00€200mg1,485.00€(S)-Sunvozertinib
CAS:(S)-Sunvozertinib (DZD9008) is a rationally designed selective, irreversible EGFR/HER2 inhibitor.Formula:C29H35ClFN7O3Purity:99.64%Color and Shape:SolidMolecular weight:584.08Branebrutinib
CAS:Branebrutinib (BMS986195) is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family.Formula:C20H23FN4O2Purity:95.86% - 99.31%Color and Shape:SolidMolecular weight:370.42Spebrutinib
CAS:Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplasticFormula:C22H22FN5O3Purity:97.02% - >99.99%Color and Shape:SolidMolecular weight:423.44Acalabrutinib
CAS:Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.Formula:C26H23N7O2Purity:98.94% - 99.64%Color and Shape:SolidMolecular weight:465.51Ref: TM-T3626
5mg44.00€1mL*10mM (DMSO)48.00€10mg57.00€25mg78.00€50mg90.00€100mg144.00€200mg215.00€500mg355.00€Ibrutinib
CAS:Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.Formula:C25H24N6O2Purity:98% - 99.95%Color and Shape:SolidMolecular weight:440.50BTK IN-1
CAS:BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
Formula:C19H21ClN6OPurity:97.38%Color and Shape:SolidMolecular weight:384.86Avitinib
CAS:Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor,Formula:C26H26FN7O2Purity:99.81% - >99.99%Color and Shape:SolidMolecular weight:487.53Tolebrutinib
CAS:Tolebrutinib is an oral, selective BTK inhibitor, effective for MS research, with brain penetration and IC50s of 0.4/0.7 nM in cells.Formula:C26H25N5O3Purity:98.4% - 98.82%Color and Shape:SolidMolecular weight:455.51Ref: TM-T9125
2mg40.00€5mg71.00€1mL*10mM (DMSO)80.00€10mg105.00€25mg177.00€50mg264.00€100mg434.00€200mg622.00€BTK Protein, Human, Recombinant (His)
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling.Purity:90%Color and Shape:Lyophilized PowderMolecular weight:78.3 kDa (predicted)Ibrutinib-d5
CAS:Ibrutinib D5 is a deuterium-labeled Ibrutinib. Ibrutinib is an irreversible Btk inhibitor.Formula:C25H24N6O2Purity:98%Color and Shape:SolidMolecular weight:445.53CP-547632
CAS:CP-547632 is an oral ATP-competitive inhibitor of VEGFR-2/FGF kinase with IC50s of 11/9 nM, highly selective, has antitumor activity.Formula:C20H24BrF2N5O3SPurity:99.14%Color and Shape:SolidMolecular weight:532.4JNJ-64264681
CAS:JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK).Formula:C27H30N6O3SPurity:98%Color and Shape:SolidMolecular weight:518.63BTK inhibitor 10
CAS:BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.Formula:C25H23N5O3Purity:98%Color and Shape:SolidMolecular weight:441.48SJF620
CAS:SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).Formula:C41H44N8O7Purity:98%Color and Shape:SolidMolecular weight:760.84PF-06658607
CAS:PF-06658607 is an alkynylated irreversible Brutons tyrosine kinase (BTK) inhibitor.Formula:C27H24N6O2Color and Shape:SolidMolecular weight:464.52PF-06465469
CAS:PF-06465469, a covalent ITK and BTK inhibitor (IC₅₀ = 2 nM), suppresses CXCL12-mediated migration and decreases PD-1/LAG-3 for leukemia and lymphoma research.Formula:C30H33N7O2Purity:98%Color and Shape:SolidMolecular weight:523.63VA5 TG2 inhibitor
CAS:VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.Formula:C31H34N4O8Purity:98%Color and Shape:SolidMolecular weight:590.62ACP-5862
CAS:ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.Formula:C26H23N7O3Color and Shape:SolidMolecular weight:481.51CGI560
CAS:CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.Formula:C29H27N5OColor and Shape:SolidMolecular weight:461.56BLK-IN-1
CAS:BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.Formula:C29H23F3N6O3Color and Shape:SolidMolecular weight:560.53DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Formula:C25H26ClN7O3Color and Shape:SolidMolecular weight:507.97(R)-Elsubrutinib
CAS:(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor and an isomer of Elsubrutinib, suitable for inflammation research.Formula:C17H19N3O2Purity:99.05%Color and Shape:SolidMolecular weight:297.35Ref: TM-T72653
1mg145.00€5mg250.00€10mg340.00€1mL*10mM (DMSO)462.00€25mg573.00€50mg879.00€100mg1,314.00€JAK3/BTK-IN-6
CAS:JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.Formula:C21H17BF3N5O3Color and Shape:SolidMolecular weight:455.2CHMFL-BTK-01
CAS:CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.Formula:C38H41N5O5Purity:98%Color and Shape:SolidMolecular weight:647.76BI-1622
CAS:BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.Formula:C26H24N10O2Color and Shape:SolidMolecular weight:508.53EGFR-IN-40
CAS:EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).Formula:C23H20N6O3Color and Shape:SolidMolecular weight:428.44Ibrutinib-MPEA
CAS:Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Formula:C32H39N9O2Color and Shape:SolidMolecular weight:581.71
